Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825398 | 1.00 | PDCD1 (0.50) | PDCD1CD274PDE4APDE4BPDE4C | |
| SCHEMBL6239161 | 0.85 | PTGES2 (0.46) | TRPV4MEN1KMT2APTGES2KDM4C | |
| SCHEMBL712489 | 0.84 | MAPT (0.57) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL11313806 | 0.83 | MAPT (0.59) | TRPV4MEN1KMT2AMAPTPTGES2 | |
| SCHEMBL8680801 | 0.82 | MAPT (0.44) | PDCD1CD274PDE4APDE4BPDE4C | |
| SCHEMBL1838256 | 0.82 | ACLY (0.50) | TRPV4MEN1KMT2APTGES2KDM4C | |
| SCHEMBL8151401 | 0.82 | TRPV4 (0.52) | TRPV4MEN1KMT2AMAPTPTGES2 | |
| SCHEMBL2152147 | 0.82 | TTR (0.47) | TRPV4MEN1KMT2AMAPTPTGES2 | |
| SCHEMBL3325248 | 0.81 | CYP1A2 (0.49) | MEN1KMT2AMAPTKDM4CSLC6A4 | |
| SCHEMBL17913144 | 0.80 | PDE4A (0.59) | PDCD1CD274PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559582-B2 | Polyacrylate polymer | BASF SE (DE) | 2026-02-24 | — | — | US | claimed |
| EP-3898730-A1 | POLYACRYLATE POLYMER | BASF SE (DE) | 2021-10-27 | — | — | EP | claimed |
| CN-113195564-A | Polyacrylate polymers | 巴斯夫欧洲公司 | 2021-07-30 | — | — | CN | claimed |
| WO-2020127463-A1 | POLYACRYLATE POLYMER | BASF SE (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-3160977-A2 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS | The University of Kansas (US) | 2017-05-03 | — | — | EP | claimed |
| WO-2015200514-A2 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS | THE UNIVERSITY OF KANSAS (US) | 2015-12-30 | — | — | WO | claimed |
| US-12559582-B2 | Polyacrylate polymer | BASF SE (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| CN-119874674-A | GLP-1R modulating compounds | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4508047-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1216980-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559582-B2 | Polyacrylate polymer | SAAL1, ATXN2L, VCL | PDCD1 4467/4885CD274 3033/4885PDE4A 4336/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PDCD1 1085/4885CD274 1698/4885PDE4A 92/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | PDCD1 1233/4885CD274 2091/4885PDE4A 64/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | PDCD1 667/4885CD274 779/4885PDE4A 3831/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | PDCD1 3915/4885CD274 3681/4885PDE4A 1286/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | PDCD1 2457/4885CD274 3049/4885PDE4A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.